Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161051 · ClinicalTrials.gov registry record
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 287
- Enrollment target
NCT06161051: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06161051 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 287 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161051 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 287 participants
- Enrollment target
Study Summary
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2022-12-07 |
What the finished NCT06161051 record still lists
NCT06161051 is an observational study that tracks outcomes without assigning an intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06161051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06161051 about?
NCT06161051 is a clinical study titled "Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States". This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data ab...
What is the current status of trial NCT06161051?
This trial is currently completed. The enrollment target is 287 participants. The study started on 2022-10-03. Estimated completion is 2022-12-07.
Who is sponsoring clinical trial NCT06161051?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI